Bone is the most frequent site of metastasis in prostate cancer and patients with bone metastases are deemed incurable. Targeting prostate cancer cells that disseminated to the bone marrow before surgery and before metastatic outgrowth may therefore prevent lethal metastasis. This prompted us to directly analyze the transcriptome of disseminated cancer cells (DCC) isolated from patients with nonmetastatic (UICC stage M0) prostate cancer. We screened 105 bone marrow samples of patients with M0-stage prostate cancer and 18 bone marrow samples of patients without malignancy for the presence of EpCAM þ single cells.
Introduction
Despite substantial investment into cancer research, metastasis-the cause of more than 90% of cancer-related deaths (1)-remains poorly understood. Delineating early steps of metastasis before detection of manifest lesions by clinical imaging techniques may provide chances to prevent lethal outcome. After a short period of circulation in the blood (when they are termed circulating tumor cells, CTC), disseminating cancer cells lodge in distant organs and are termed disseminated cancer cells (DCC). Obviously, cancer cells remaining in the body of M0-stage patients after surgical removal of the primary tumor comprise founders of later arising lethal metastases and therefore DCCs are the target population of systemic adjuvant therapies. In support of this notion are numerous reports on the prognostic impact of DCCs, which are commonly detected by the histogenetic markers, EpCAM or cytokeratins (CK), in lymph nodes and bone marrow, respectively. In contrast to CTCs, which are mostly detected and studied in patients with metastases (2), DCCs are clearly relevant in early disease stages (3) (4) (5) .
We previously showed that the presence of CK-positive (CK þ ) DCCs in the bone marrow of M0-stage prostate cancer patients is associated with shorter metastasis-free survival (5) . Genetic studies of isolated CK þ DCCs demonstrated marked heterogeneity of M0-stage DCC genomes within and between patients (5, 6). However, little is known about phenotypic characteristics of DCCs. Survival data suggest the existence of DCCs with different metastasis-initiating potential, as not all patients with DCCs develop metastasis. Furthermore, the fact that some patients without CK þ cells in bone marrow develop metastasis points to the existence of subpopulations of DCCs undetected by current markers. This is particularly true for prostate cancer where the increase of prostate-specific antigen (PSA) after radical prostatectomy (biochemical relapse) is not associated with increasing numbers of CK þ cells in bone marrow (5) . Therefore, targeting metastasis founder cells requires detailed molecular characterization of DCCs. One hindrance to such characterization is the low frequency of M0-stage DCCs, with a median number of 1 to 2 DCCs per 10 6 bone marrow cells of positive patients. Previously, we established an approach to comprehensively characterize the transcriptome of a single cell using microarrays (7, 10) . As cytokeratins are intracellular proteins, comprehensive analysis of a single DCC transcriptome requires use of a surface marker such as EpCAM for their detection. Furthermore, detection of EpCAM-positive (EpCAM þ ) cells in bone marrow has also been associated with prostate cancer progression (8) . However, unlike CK þ cells (9) , EpCAM þ cells are often found in the bone marrow of healthy individuals (10, 11) , thereby confounding molecular studies of DCCs. Hence, there is an urgent need for an assay to reliably select true DCCs for transcriptome analysis using microarrays. Here, our aim was to detect and isolate EpCAM þ cells from the bone marrow of M0-stage prostate cancer patients and healthy controls for detailed characterization of their gene expression. 
Materials and Methods
The workflow of this study is given in the Supplementary  Fig. S1 .
Patients and bone marrow samples
The local ethics committee of the University of Regensburg (Regensburg, Germany) approved all aspects of the study (ethics vote number 07-079). Between February 2009 and November 2012, bone marrow aspirates from 105 nonmetastatic (M0 stage) prostate cancer patients were collected shortly before radical prostatectomy. In addition, we obtained bone marrow samples of two metastatic (M1 stage) prostate cancer patients. As a control group, 18 bone marrow samples from cancer-free males undergoing trauma or orthopedic surgery were obtained. After obtaining written informed consent, the sampling was performed by aspiration of the left and right iliac crest (12) . The samples were transported to the laboratory within 3 hours and subjected to further processing. Baseline patient characteristics are provided in Table 1 .
Processing of bone marrow samples
Detailed description of bone marrow processing is given in Supplementary Materials and Methods. Briefly, upon arrival, the bone marrow sample was twice washed with Hank's balanced salt solution to remove fat and thrombocytes. Next, cell suspension was centrifuged in density gradient. After centrifugation, the interphase containing mononuclear cells (MNC) were carefully collected and washed with PBS. The number of MNCs and erythrocytes was determined on hemocytometer. To enrich the DCC-containing fraction, the sample was depleted of the majority of hematopoietic cells using negative immunomagnetic selection. This was done by incubating the cell suspension with APC-conjugated antibodies against CD11b, CD33, and CD45. After incubation and washing, the cell suspension was incubated with anti-APC beads and anti-CD235a beads (glycophorin A). After incubation and washing, the cell suspension was run through the 40-mm cell sieve, and then run on LS MACS column. The eluate, containing the unlabeled cell fraction, was collected on ice and the cell number determined using a hemocytometer.
Staining of bone marrow samples and cell lines
Detailed description of staining procedure is given in Supplementary Materials and Methods. On average, two million bone marrow cells were stained with anti-EpCAM-PE (HEA125, Miltenyi Biotec) antibody. Cell lines (WPE-Stem, DU145, PC3, WPE-Int, LNCaP, and VCaP) were grown according to instructions from ATCC. At 80% confluence, the medium was discarded, cell monolayer washed with PBS, and cells fixed using 4% formaldehyde. Further immunostaining steps were performed as described with the addition of nuclear counterstaining using DAPI ( Supplementary Fig. S2 ).
Screening of bone marrow and isolation of single cells and cell pools
A detailed description of the screening and cell isolation procedures is given in Supplementary Materials and Methods. Each bone marrow sample was manually screened for the presence of EpCAM þ cells on an inverted fluorescent microscope (Olympus or Zeiss), equipped with micromanipulator (Patchman NP2, Eppendorf) and pump (CellTram, Eppendorf). Single cells with preserved integrity and positively stained for EpCAM were extracted using a glass capillary attached to the micromanipulator. By visual inspection, we ensured that only one cell was in the capillary. The cell was transferred to an empty field with PBS and manually isolated using a micropipette. After isolation of single EpCAM þ cells from each sample we isolated a pool of approximately 2,000 to 3,000 cells. As a reagent control of cell isolation, 1 mL of PBS, in which individual EpCAM þ cells were isolated, was taken for subsequent whole transcriptome amplification (WTA). Photographs of the cells before isolation were made in 10 cases, using the software cellSens (Olympus) or AxioVision (Zeiss). Because of the rapid bleaching of PE fluorophore, we abstained from taking photographs of all isolated cells.
Flow-cytometric analysis of bone marrow cells was performed with a LSR II machine equipped with FACS DIVA 5.03 software (BD Biosciences) and data was analyzed with FlowJo 8.8.6 (Treestar). out as previously described (7, 10) . Details are provided in Supplementary Materials and Methods. The quality of amplification was examined by performing endpoint PCR for ACTB, EEF1A1, and GAPDH transcripts (see below and Supplementary Table S1 ).
Whole transcriptome amplification controls
From all samples, WTA controls were generated by aspirating 1 mL buffer without a cell from the slide after DCC isolation and equally subjected to WTA. After WTA, we controlled for the presence of ACTB, EEF1A1, and GAPDH transcripts. Only when WTA controls were negative, cells isolated during the same experiment were included into transcriptome analysis. In 2 of 125 (2%) bone marrow samples, the WTA control was contaminated. The WTA samples of these two patients were excluded from genome and transcriptome analysis.
Whole genome amplification and comparative genomic hybridization
Single-cell genomic DNA collected during WTA procedure was precipitated and subjected to whole genome amplification (WGA), using the Ampli1 WGA Kit (Silicon Biosystems), as described previously (10, 13) . Details are provided in Supplementary Materials and Methods. CGH on metaphases (cCGH, n ¼ 24 samples) and Agilent microarrays (aCGH, n ¼ 18 samples) was performed as described previously (10, 13, 14) . Array files are deposited in GEO database under accession number GSE59631.
Expression analysis of selected transcripts by endpoint PCR in patient samples
All WTA products were tested by endpoint PCR using conditions outlined in Supplementary Materials and Methods. The list of primers is given in Supplementary Table S1. To establish the correct identity of each amplified fragment, we performed restriction digestion, using the conditions outlined in Supplementary Materials and Methods. Only after a positive result after digestion, the sample was declared positive for a given transcript.
Statistical analyses
Statistical analyses were performed using SPSS v22 (IBM). Hierarchical clustering was performed using the software tool Cluster (15) . Supplementary Fig. S7A ). In addition, high-quality WTA products of bone marrow cell pools from ten randomly selected M0-stage patients, one M1-stage patient, and ten controls were chosen for further analysis.
Results

Detection of EpCAM
Expression profiling for identification of a DCC signature in M0-stage patients We started the search for a DCC-specific signature by expression analysis of selected genes in bone marrow cell pools of prostate cancer patients and controls. We could not detect significantly different frequencies for epithelial-, prostate-, tumor-associated, and erythroid transcript expression between the analyzed cell pools (Supplementary Table S3 ; Supplementary Figs. S6 and S8D-S8F) . Surprisingly, among common hematopoietic transcripts, only CD19 was expressed in a significantly higher number of samples from M0-stage patients as compared with pools from healthy controls (P < 0.05, Fisher exact test).
As the analysis of bone marrow cell pools revealed no transcript specific for cancer patients or controls, we focused on expression profiling of selected transcripts in EpCAM Table S3) .
Forty-two percent of cells from M0-stage patients expressed at least one KRT transcript ( Supplementary Fig. S7B ), 2 ). The difference between patients with cancer and controls was even more pronounced, when we analyzed KRT expression in EPCAM-transcript-positive cells. We found that cells from M0-stage patients more frequently coexpressed EPCAM and KRT transcripts, compared with cells from controls (P < 0.002, Fisher exact test; Supplementary  Table S4 ). Among KRT-expressing cells from M0-stage patients, the most frequently detected KRT transcripts were KRT8 and KRT18 (Fig. 2 and Supplementary Fig. S7C ; Supplementary Table S3 ). These transcripts were detected significantly more often in cells from M0-stage patients than in controls (KRT8, 30% vs. 4%, P < 0.01; KRT18, 27% vs. 7%, P < 0.05; Pearson c 2 ; Supplementary Table S3) . KRT19, KRT14, and KRT6a transcripts were found in less than 5% of cells from M0-stage patients, and were absent in cells from controls. No KRT5 transcripts were detected in cells of either group (Supplementary Table S3 and Supplementary  Fig. S7C ). In total, among cells from M0-stage patients, 93% of cells expressed at least one of the tested epithelial transcripts, compared with 57% cells from controls (P < 0.001, Fisher exact test). This distribution closely resembled the frequency of EPCAM expression observed in these two groups of cells (Supplementary Fig. S7B ).
Next, we analyzed prostate-and tumor-specific transcripts. KLK3 (PSA) transcript was found only in cells isolated from one M0-stage patient, whose bone marrow cell pool also expressed KLK3. Overall, this transcript was detected in 9 (7%) M0-stage cells and was absent in cells from controls (P ¼ 0.143, Fisher exact test; Fig. 2; Supplementary Table S3 ). MAGEA2 and MAGEA4 transcripts could not be found in any of the EpCAM þ single cells.
Given the rare detection of histogenetic or cancer-associated epithelial transcripts, we sought to determine whether hematopoietic transcripts are useful to differentiate between EpCAM þ cells from cancer versus control patients.
For this, we analyzed the expression of selected hematopoietic transcripts. To our surprise, among cells from M0-stage cancer patients, the PTPRC transcript (CD45) was most frequently detected (19% of cells; Fig. 2 Table S3) . In single cells, the frequencies of hematopoietic transcript expression did not differ significantly (P ¼ 0.5; Pearson c 2 ). We then analyzed the expression of selected erythroid lineage-specific transcripts, GYPC (CD236, glycophorin C), SCL4A1 (CD233, band 3 protein), and HBA2 (hemoglobin a2). Frequencies of erythroid transcript-expressing cells between M0-stage patients and controls were almost identical (P ¼ 0.5, Pearson c 2 ). Here, the most frequently detected transcript was HBA2 and it was detected in 93% of cells from M0-stage patients and in 86% of cells from controls ( Fig. 2 ; Supplementary   Table S3 ). Overall, 96% of cells from M0-stage patients expressed at least one erythroid transcript, while the frequency of such cells among control cells was 93%.
This unexpected observation prompted us to control whether extracellular erythroid transcripts may contaminate the single-cell transcriptomes by mRNA carryover or release during sample processing. Therefore, we checked the WTA controls (see Materials and Methods section for details) of 40 patients for the presence of HBA2 transcript. As all 40 samples were negative ( Supplementary Fig.  S9 ) we note a striking difference to the cell-containing samples of M0-stage prostate cancer patients (P < 0.0001, Pearson c 2 ). Overall, analysis of epithelial, hematopoietic, and erythroid transcripts in EpCAM þ single cells from cancer patients and controls revealed unexpected transcriptomes ( Fig. 3 and Supplementary Fig. S8A and S8B ). Table S1 and Supplementary Fig. S11 . Identifiers of the samples are given above the wells, and the identity of analyzed transcript is given next to each cropped gel. Only those samples that contain the band of correct size were considered positive. The brightness and contrast of each individual cropped image were manipulated by using the "Auto contrast" tool of Adobe Photoshop.
Expression profiling of cells from M1-stage patients
For the majority of analyzed genes, EpCAM þ single cells or cell clusters from M1-stage cancer patients displayed similar frequencies of transcript-positive cells similar to those from M0-stage patients (Fig. 2, Fig. 3 , and Supplementary Fig. S7B ; Supplementary Table S3 ). A detailed overview of coexpression of individual transcripts is given in Supplementary Fig. S8C . (Fig. 4A) .
Analysis of genomic aberrations
The presence of hematopoietic transcripts in EpCAM þ single cells from patients with prostate cancer casted doubts whether these are indeed cancer cells, although many of them coexpressed epithelial transcripts. This prompted us to analyze selected cells for the presence of genomic aberrations using CGH. While the absence of genomic aberrations at the given resolution does not prove that the analyzed cell is not a cancer cell (16) , the presence of genomic aberrations confirms the malignant origin of the cell.
To demonstrate the reliability of our combined genome and transcriptome analysis, we first compared the profile of a single VCaP cell with the profile of VCaP unamplified genomic DNA and found that the majority of genomic aberrations could be retrieved at single cell genome level (Supplementary Fig. S10A ). In contrast, two peripheral blood leukocytes from a healthy volunteer displayed normal karyotypes (Supplementary Fig.  S10B ).
Next, we analyzed the genome of four EpCAM þ cells from controls, and 34 EpCAM þ cells isolated from the bone marrow of M0-and M1-stage patients using CGH. No aberrations could be detected in the genomes of four EpCAM þ cells from controls, (Supplementary Fig. S10C ), whereas 13 of 34 cells (38%) from patients had genomic aberrations. Strikingly, we found cells expressing hematopoietic (e.g., CD45) or erythroid (e.g., HBA2) transcripts, and harboring genomic aberrations, both in M0-and M1-stage patients ( Fig. 5 and Supplementary  Fig. S10E ). These data demonstrate that DCCs can express hematopoietic and erythroid transcripts. Finally, we compared the 17-gene signature of EpCAM þ cells from patients with prostate cancer (M0 and M1 stage) versus EpCAM þ cells selected for genomic aberrations. Overall, the expression patterns did not change, although we noted an increased frequency of cells expressing epithelial transcripts (KRT8, KRT18; KRT19; KRT6a, EPCAM) among cells harboring genomic aberrations. Furthermore, erythroid marker expression was clearly detectable in these cells similar to the whole cohort (e.g., HBA2 was detected in 77% vs. 92% and CD45 in 15% vs. 18%, respectively). A potentially relevant change was observed for PSA (KLK3). Here, cells harboring genomic aberrations more often expressed the transcript than the whole group of EpCAM þ cells from patients with prostate cancer (P ¼ 0.02; Fisher exact test; Fig. 6 ).
Discussion
In this study, we performed targeted expression profiling of EpCAM þ single cells isolated from the bone marrow of patients with nonmetastatic (M0 stage) prostate cancer and demonstrate, contrary to our expectation, that a 17-gene mRNA signature based on selected histogenetic markers is insufficient to reliably identify DCCs. However, by combining genome and transcriptome analysis, we could show that prostate cancer-DCCs mimic the transcriptomes of bone marrow cells and harbor hematopoietic and particularly erythroid transcripts. These findings suggest a high phenotypic plasticity of cancer cells clearly surpassing the classical concept of epithelial-mesenchymal transition (17) . We started by analyzing cell pools of CD45-, CD33-, CD11b-, and glycophorin A-depleted bone marrow cells from patients with prostate cancer and controls, reasoning that one or several markers should be able to classify cancer-derived samples correctly. As this was not the case, we focussed on individually isolated single EpCAM-positive cells expecting that this population contained bona fide DCCs with a defined transcriptional profile.
EpCAM protein expression appeared to be stronger in cells from patients with prostate cancer than controls. However, the percentage of positive samples was comparable between groups and reliable identification of DCCs based on EpCAM staining alone was not possible (10, 11, 18) . Of note, EpCAM expression by putative DCCs in bone marrow was rather low compared with the typical appearance of most prostate cancer cell lines (19, 20) . Consequently, we investigated whether our marker panel, comprising epithelial (EPCAM, KRT8, KRT18, KRT19, KRT14, KRT6a, KRT5), the prostate-specific KLK3 (PSA), tumor-associated (MAGEA2, MAGEA4) and hematopoietic transcripts [PTPRC (CD45), CD33, CD34, CD19, GYPC, Our findings have important implications for the study of metastasis. First, an educated guess for CTC or DCC-specific markers seems highly unreliable. So far, many studies assume histogenetic specificity (37) that we could not confirm for transcriptomes of bone marrow-derived DCCs. Likewise attempts to reconstruct cancer cell transcriptomes from unpurified CTCs by transcript subtraction need to be viewed with caution (38) . Our findings are consistent with previous observations, such as a transcriptome study of 15 single prostate CTCs from one M1-stage patient revealing low-level expression of EPCAM, PTPRC (CD45), and CD34 (39), expression of hemoglobins in breast cancer epithelial cells (40, 41) and ovarian cancer epithelial cells transdifferentiating into erythroid cells expressing hemoglobins (42) . The observed expression of hematopoietic and erythroid transcripts by bone marrow-DCCs may reflect adaptation to the specific environment. Of note, it was shown that metastatic prostate cells compete with hematopoietic stem cells (HSC) for the HSC niche (43) . If DCCs indeed reside in the HSC niche, it is possible that crosstalk between DCCs and bone marrow cells, mediated by cell-cell interaction or secreted factors, leads to expression of hematopoietic transcripts in DCCs. Furthermore, the transcriptomes of DCCs could be altered by the uptake of exosomes released from resident bone marrow cells (44) or our observations could be the consequence of hypoxic/oxidative stress imposed on DCCs within the bone marrow microenvironment (45, 46) . While additional studies are needed to identify the underlying causes, the observed altered transcriptomes are likely to result in altered phenotypes and cell function, which may be highly relevant for our attempts to tailor cancerspecific therapies.
In summary, until a comprehensive analysis of genes expressed by EpCAM þ cells of patients with prostate cancer versus EpCAM þ cells of controls is performed, we will struggle to identify new markers specific for DCCs or confounding cells of nonepithelial lineage. Detection of genomic aberrations currently seems to be the most reliable way to confirm cancer cell identity.
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